Please assess the completion status of the following clinical trial:

Trial Title: A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor~* Part 1A: Participants with solid tumors where anti-PD-(L)1 is an established treatment. Participants must have progressed on or following prior anti-PD-(L)1 therapy if approved, available, tolerable, and eligible~* Part 1B: Participants either meeting Part 1A criterion, or participants with cold solid tumors where anti-PD-(L)1 therapy is not an established treatment~* Part 2: Participants with NSCLC (Arm A) must have received platinum-based chemotherapy and anti-PD-(L)1 or have intolerability to or refusal of standard therapies. NSCLC participants with known activating mutation(s) must also have received prior approved and available targeted therapy(ies) for the associated mutation(s) or have intolerability or documented refusal of these therapies. Participants with UC (Arm B) must have received prior platinum-based chemotherapy, anti-PD-(L)1 therapy, or enfortumab vedotin, or have documented intolerability or refusal of the standard therapy(ies). Additional cohort indication(s) or dose regimens may be added and defined based on emerging data~* At least 1 measurable lesion based on RECIST 1.1 that has not been previously irradiated (Part 1 exceptions permitted after review and approval)~* Able to provide pre-treatment (and optional on-treatment) tumor tissue~Exclusion Criteria:~* Active or history of clinically significant gastrointestinal disease and other conditions that are unresolved or pose a risk to study treatment or procedures~* Active or history of pneumonitis/interstitial lung disease, pulmonary fibrosis requiring treatment with systemic steroid therapy~* Active or history of clinically significant autoimmune disease or other medical condition that required chronic systemic immunosuppressive therapy within recent 2 years~* History of severe immune-mediated adverse event or cytokine release syndrome that was considered related to prior immune modulatory therapy that required immunosuppressive therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monotherapy dose escalation (Part 1A) (Type: EXPERIMENTAL): Participants will receive PF-07820435 orally at the prescribed dose and frequency in 28-day cycles
- Combination dose escalation (Part 1B) (Type: EXPERIMENTAL): Participants will receive PF-07820435 orally at the prescribed dose and frequency, in combination with sasanlimab (subcutaneous injection) at a fixed dose once every 4 weeks in 28-day cycles
- Expansion (Part 2) - Tumor specific Arm A (Type: EXPERIMENTAL): Participants will receive PF-07820435 orally at the prescribed dose and frequency in combination with sasanlimab SC once every 4 weeks in 28-day cycles
- Expansion (Part 2) - Tumor specific Arm B (Type: EXPERIMENTAL): Participants will receive PF-07820435 orally at the prescribed dose and frequency in combination with sasanlimab SC once every 4 weeks in 28-day cycles
- Expansion (Part 2) - Arm C (Type: EXPERIMENTAL): Participants will receive PF-07820435 orally at the prescribed dose and frequency in 28-day cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy